{"schema_version":"secwatch.filing_event.v1","accession":"0001174947-24-000582","form_type":"8-K","ticker":"CNMD","cik":"0000816956","company_name":"CONMED Corp","filed_at":"2024-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.062177+00:00","generated_at":"2026-06-03T10:35:47.422176+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CONMED Q1 2024: revenue up 5.7% to $312.3M; adjusted EPS $0.79 beats; guidance trimmed on FX headwinds","bullets":["GAAP diluted EPS $0.63 vs $0.06 in Q1 2023; adjusted EPS $0.79, up 19.7% YoY.","Revenue $312.3M (+5.7% as reported, +5.9% constant currency); domestic +7.2%, international +3.8%.","General Surgery revenue grew 8.0% as reported; Orthopedic Surgery +2.8%.","FY2024 revenue guidance lowered to $1.330-1.355B (prev $1.340-1.365B) due to ~$10M FX headwind.","Adjusted EBITDA $56.3M, margin 18.0% vs 17.3% in Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001174947-24-000582","json":"https://secwatch.observer/filing/0001174947-24-000582.json","markdown":"https://secwatch.observer/filing/0001174947-24-000582.md","text":"https://secwatch.observer/filing/0001174947-24-000582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/816956/000117494724000582/0001174947-24-000582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/816956/000117494724000582/form8k-32144_cnmd.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T10:35:47.422176+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"55d7de39d75e8d90ec99b66e70039cbe643e96a4","claim":"CONMED Corp reported first quarter ended March 31, 2024 results: revenue $312.3 million.","evidence_excerpt":"Florida, April 24, 2024 – CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights · Sales of $312.3 million increased 5.7% year-over-year as reported and 5.9% in constant currency. · Domestic revenue increased 7.2% year-over-year. · International revenue increased 3.8% year-over-year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/816956/000117494724000582/0001174947-24-000582-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$312.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}